Yervoy (ipilimumab) - BMS
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Bavencio (avelumab) - EMD Serono
Keytruda (pembrolizumab) - Merck (MSD)
JOCARDITE: JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors (clinicaltrials.gov) - Sep 12, 2026 - P=N/A | N=500000 | Recruiting | Sponsor: Groupe Hospitalier Pitie-Salpetriere | Trial completion date: Jan 2025 ➔ Jan 2030 | Trial primary completion date: Jan 2025 ➔ Jan 2030 
Checkpoint inhibition • Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Heart Failure • Inflammation • Oncology • Vasculitis
http://clinicaltrials.gov/ct2/show/NCT04294771
 
Sep 12, 2026
 
Prev Next